Chau Q. Khuong is a biotech entrepreneur and venture capital investor. From 2003 until the end of 2021, he worked at OrbiMed Advisors, a global healthcare-dedicated investment firm with over $15 billion in assets under management.

European life science stories often struggle with U.S. investors for a variety of reasons. This meeting is a unique opportunity to discuss with one of the most experienced U.S. life science investors how to make your story resonate with U.S. investors. Chau also has extensive investment experience in Europe, most recently with Evox Therapeutics in Oxford.

Chau Q. Khuong is a biotech entrepreneur and venture capital investor. From 2003 until the end of 2021, he worked at OrbiMed Advisors, a global healthcare-dedicated investment firm with over $15 billion in assets under management. At the time of his retirement from OrbiMed, Mr Khuong was Partner and member of the investment committee for the OrbiMed venture capital funds.  Over the past 20 years, he has been an active lead investor in innovative drug development and medical device enterprises across all stages and therapeutic areas including oncology, infectious diseases, ophthalmology, gene therapy and gene editing.

Mr. Khuong serves and has served in a board capacity of numerous public and private companies, including Evox Therapeutics, Arius Research (acquired by Roche), Durata (acquired by Actavis), Bellus Health (NASDAQ: Blu), Synlogic, Inc. (NASDAQ: SYBX), Fusion Pharmaceuticals (NASDAQ: FUSN), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals (NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP), NextCure (NASDAQ: NXTC), Pieris (NASDAQ: PIRS), Rempex (acquired by Medicines Company) and Nabriva Therapeutics. He holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious diseases, both from Yale University.